Menu

Compound Found in Red Wine Boosts Immune Cell Function

At low doses, resveratrol enhanced human T-cell activity in vitro, while at high doses it interfered with cell signaling. 

Oct 16, 2017
Catherine Offord

ISTOCK, ALEXPRO9500A compound found in red wine that has been linked to a diverse range of therapeutic properties in lab animals has now been shown to enhance human T-cell function, but only at low doses, according to a study published today (October 17) in Science Signaling. Small amounts of resveratrol made cultured CD4+ T cells more responsive to target antigens, researchers found, while larger amounts triggered defective antigen receptor signaling.

“This pharmacological agent has elicited much interest because of its potential to modulate a diverse array of pathological conditions, and it is associated with anticancer, antiaging, and anti-inflammatory properties,” the authors write in their paper. “The data shown here reveal a complex network of resveratrol-stimulated changes in cell cycle progression and metabolism, altering the potential of T lymphocytes to respond to foreign antigens.”

See “Resveratrol’s Low-Dose Anticancer Effect

A polyphenol found in grapes, resveratrol has been shown to prolong life in worms and fruit flies through the activation of SIRT1, an enzyme involved in T-cell signaling and cytokine production. But even after multiple clinical trials, researchers have failed to conclusively demonstrate an extension of these positive effects to humans.

See “Resveratrol May Not Extend Life

In the current study, researchers at the Institute of Molecular Genetics of Montpellier in France showed that, presented with low doses of resveratrol, the SIRT1 protein was activated in human T cells via the mTOR signaling pathway and led to improved T-cell function in vitro. This effect was reversed when the dose was increased, with cells showing impeded mTOR signaling and reduced SIRT1 stimulation.

“Our data suggest that resveratrol is an agent that, by altering the metabolic fitness of T lymphocytes, enhances their cytokine effector potential,” the authors write. Now, they add, “the potential use of resveratrol as a therapy for the treatment of neurological, cardiovascular, hepatic, and metabolic pathologies . . . necessitates a critical evaluation of its effect on T lymphocytes in vivo.”

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.